Neuland Laboratories Ltd (NEULANDLAB)
🎯 Key Takeaways
- Neuland Laboratories Ltd is transitioning from a high-growth, cyclical phase into a more stable, capital-efficient expansion stage, supported by strong profitability and improving credit metrics. Management is actively investing in capacity and product diversification while maintaining conservative leverage, positioning the company for sustained mid-term growth in the global API market.
- Revenue declined 17.3% QoQ to ₹642 in Q1FY27.
- ⚠️ 1) Margin compression due to rising input costs and operational scaling challenges in new facilities remains a near-term concern. 2) Geopolitical and
- Market Cap
- ₹27,498
- P/E Ratio
- 55.2
- P/B Ratio
- 14.67
- ROE
- 26.6%
- ROCE
- 33.6%
- Debt/Equity
- 0.10
- Div Yield
- 0.16%
- Promoter
- 32.6%
📖 The Story
Neuland Laboratories Ltd is transitioning from a high-growth, cyclical phase into a more stable, capital-efficient expansion stage, supported by strong profitability and improving credit metrics. Management is actively investing in capacity and product diversification while maintaining conservative leverage, positioning the company for sustained mid-term growth in the global API market.
📰 What's Happening
In Q1FY27, Neuland reported robust financial performance with revenue of ₹642 crore and operating profit of ₹196 crore, though margins moderated to 30.6% from 36.4% in the prior quarter due to operational volatility. Management has consistently highlighted ongoing capacity expansions in the US and Europe, with board-level discussions underway for future investments. The CRISIL rating upgrade in August 2026 underscores improved financial resilience, enabling greater flexibility in capital allocation. Additionally, the company has maintained a disciplined shareholding pattern, with promoter holding stable near 32.6% over multiple quarters.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 514 | 440 | 776 | 642 |
| Operating Profit | 133 | 53 | 282 | 196 |
| OPM % | 25.9% | 12.1% | 36.4% | 30.6% |
| Net Profit | 97 | 41 | 213 | 148 |
| EPS | ₹75.49 | ₹31.62 | ₹165.76 | ₹115.10 |
Revenue has shown significant quarter-on-quarter growth, rising from ₹440 crore in December 2025 to ₹642 crore in June 2026, driven by increased order intake and global demand. However, operating margins have declined from 36.4% to 30.6% over the same period, reflecting higher input costs and production inefficiencies during scaling. Despite this, net profit remains resilient at ₹148 crore, supported by cost management and scale benefits. Management attributes margin pressure to temporary factors and expects improvement through operational stabilization and product mix optimization.
🔮 Management Outlook & What's Next
Management has indicated that the next 12–18 months will focus on scaling up newly commissioned facilities in the US and Europe to meet growing demand from regulated markets. They emphasized that investments will be phased and capital-efficient, with no aggressive leverage. While no formal revenue guidance was provided, management expressed confidence in sustaining double-digit growth, underpinned by a healthy order backlog and long-term contracts with global pharma clients.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 |
| Reserves | 1,512 | 1,382 | 1,862 | 1,607 |
| Borrowings | 157 | 109 | 197 | 265 |
| Total Liabilities | 2,180 | 1,944 | 2,930 | 2,534 |
| Fixed Assets | 674 | 531 | 1,178 | 788 |
| Investments | 109 | 105 | 2 | 114 |
| Total Assets | 2,180 | 1,944 | 2,930 | 2,534 |
The balance sheet reflects a strong equity base with minimal debt, as borrowings remain low at ₹197 crore despite rising assets. Reserves have grown steadily, indicating retained earnings are being reinvested rather than distributed. This conservative capital structure supports ongoing expansion without diluting equity or increasing financial risk, aligning with management’s focus on sustainable growth and financial stability.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +347 |
| Investing | -424 |
| Financing | +21 |
| Net Cash Flow | -56 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 32.6% | 32.6% | 32.6% | 32.6% |
| FII | 20.6% | 20.9% | 20.5% | 21.1% |
| DII | 13.6% | 14.7% | 15.8% | 16.5% |
| Public | 24.7% | 24.3% | 23.8% | 22.9% |
| # Shareholders | 44,393 | 46,187 | 46,304 | 44,340 |
Institutional interest has shown a gradual increase, with FII holdings rising from 20.6% in Q2FY26 to 21.08% in Q1FY27, suggesting growing confidence among foreign investors. DII holdings also improved from 13.55% to 16.51% over the same period, while promoter stakes remain stable. The expanding shareholder base, now exceeding 44,000, indicates broader retail participation and reduced concentration risk.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.41 L Cr | 36.5 | 18.7% | — | 0.05 |
| DIVISLAB | 2.53 L Cr | 86.5 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.85 L Cr | 77.7 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.21 L Cr | 27.0 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.09 L Cr | 99.3 | 20.8% | — | 0.45 |
| DRREDDY | 1.02 L Cr | 31.6 | 10.1% | — | 0.17 |
| MANKIND | 1.01 L Cr | 49.3 | 13.9% | — | 0.38 |
| AUROPHARMA | 97,814 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,274 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Margin compression due to rising input costs and operational scaling challenges in new facilities remains a near-term concern. 2) Geopolitical and regulatory risks in key export markets, particularly the US and Europe, could impact order visibility and pricing. 3) High dependence on a few large customers may pressure pricing in a competitive API market. Management has not yet disclosed contingency plans for margin recovery in volatile environments.
📋 Recent Filings
- Announcement2026-09-25Neuland Laboratories has closed its insider trading window effective October 1, 2026, until 48 hours after reporting quarterly and half-yearly results…
- 🔴 Announcement2026-09-16Neuland Laboratories announced its management will attend the Goldman Sachs Global Healthcare CDMO Day in Singapore from September 23-25, 2026, as par…
- 🔴 Announcement2026-09-15Neuland Laboratories announced that its first commercial peptide manufacturing module is now operational, adding 7000L reactor capacity and 750L solid…
- 🔴 Announcement2026-09-09Neuland Laboratories announced its management will attend three upcoming investor meetings in September 2026, including sessions with Emkay Global and…
- 🟡 Board Meeting2026-09-07Neuland Laboratories announced on September 7, 2026, that its board approved ₹126 crores capital expenditure to acquire about 134 acres of land in Kak…
- 🔴 Announcement2026-08-25Neuland Laboratories Limited announced that CRISIL has reaffirmed its long-term rating at CRISIL A+ with a Positive outlook and short-term rating at C…
- Announcement2026-08-10Neuland Laboratories reported a 16.3% YoY revenue jump to INR650.1 crores in Q1FY27, driven by CMS projects, with EBITDA at INR231.1 crores (35.5% mar…
- Announcement2026-08-07Neuland Laboratories announced its participation in upcoming investor meetings, including a group session with Emkay Confluence 2026 on August 12, 202…
- Announcement2026-08-05Neuland Laboratories announced an audio recording of its August 5, 2026 earnings call for Q1 FY27, accessible via its investor portal, to comply with …
- Announcement2026-08-05Neuland Laboratories announced on August 5, 2026, that its board approved unaudited financial results for Q1 June 2026 and a 40 crore rupee corporate …
🧠 Analyst's Read
Neuland is executing a deliberate expansion strategy with improving fundamentals, but near-term margin volatility and execution risks in new geographies require close monitoring. Investors should watch for clarity on capital allocation plans and margin trajectory in the next few quarters as the company scales its global footprint.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when NEULANDLAB files new disclosures
Track NEULANDLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track NEULANDLAB — FreeFree account · 2 AI queries/day